What to Expect From Pfizer Earnings

Photo of Chris Lange
By Chris Lange Updated Published
What to Expect From Pfizer Earnings

© Thinkstock

Pfizer Inc. (NYSE: PFE) is scheduled to report its first-quarter financial results before the markets open on Tuesday. Thomson Reuters has consensus estimates calling for $0.55 in earnings per share (EPS) on $12.00 billion in revenue. In the same period of last year, Pfizer posted EPS of $0.51 and $10.86 billion in revenue.

This is a top global pharmaceutical pick at Jefferies. Pfizer has a very strong pipeline, and being the world’s largest drug manufacturer by sales value supports the Wall Street notion that the company can generate higher long-term revenues through the accelerated growth of its new drugs over the next five years.

The Treasury Department announced new rules for corporate tax inversions, which effectively scuttled Pfizer’s deal with Allergan. With the deal over, not only are the risk arbitrage funds buying the stock back, but some felt there was as much as a $5 weight on the stock. The Jefferies analysts feel that investors can once again focus on the sum-of-the-parts story, which they feel is very compelling.

Pfizer has announced that it is starting 20 clinical trials this year, and more soon after, on treatments to conquer cancer, as it also seeks to gain leadership in one of the hottest and most lucrative areas of medicine. Hedge funds seem to like the stock as a total of 22 own it now.
[recirclink id=329337]
A few analysts weighed in on Pfizer ahead of the earnings report:

  • Leerink Swann has a Market Perform rating.
  • BMO Capital Markets reiterated a Buy rating.
  • Goldman Sachs reiterated a Neutral rating with a $35 price target.
  • S&P Equity Research reiterated a Buy rating.
  • Morgan Stanley initiated coverage with an Equal Weight rating and a $35 price target.

So far in 2016, Pfizer has performed more or less in line with the broad markets, with the stock up over 2%. Over the past 52 weeks, the stock is practically flat.

Shares of Pfizer were trading at $32.68 on Monday, with a consensus analyst price target of $37.90 and a 52-week trading range of $28.25 to $36.46.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

DELL Vol: 42,366,555
NTAP Vol: 15,911,807
NOW Vol: 68,243,561
IBM
IBM Vol: 28,527,546
HPE Vol: 86,996,387

Top Losing Stocks

CTRA Vol: 73,319,495
CLX Vol: 4,744,001
RMD Vol: 3,526,686
INTC Vol: 191,680,425
SWKS Vol: 5,407,806